Circassia Partners

ASTHMA IS COMPLICATED. WE BELIEVE WE CAN MAKE IT SIMPLER.

Airway inflammation is the major underlying cause of asthma. FeNO is a biomarker of Type 2 inflammation and FeNO testing can help achieve better management and outcomes in asthma patients.

Circassia is the world leader in FeNO testing. Our NIOX® products are used by specialists around the world.

NIOX VERO®, THE GOLD STANDARD IN FENO TESTING
With over 36 million FeNO tests performed worldwide, NIOX VERO® helps healthcare professionals to accurately measure Type 2 airway inflammation.
NIOX® technology eliminates the impact of environmental nitric oxide and ensures you get an accurate FeNO result each time, every time.

NIOX VERO® can help with:
– Diagnosis: Identifying Type 2 inflammation and assisting in asthma diagnosis
– Treatment: Identifying patients likely to respond to ICS and optimising ICS dosage
– Compliance: Uncovering non-adherence to ICS treatment
– Quality of life: Predicting exacerbations and reducing exacerbation rate by up to 50% (add ‘in patients at risk’ for the US only)
– Severe asthma: Identifying appropriate patients for some biologics and monitoring response to biologics

Find out more about NIOX VERO® here:
https://niox.com

Company’s Keywords: